On ECHEMI
Home > Drugs > Urapidil sustained-release tablets

Urapidil sustained-release tablets

Function and Efficacy

Urapidil is a highly selective α1 receptor blocker with both peripheral and central effects. The peripheral vasodilator effect is mainly to block postsynaptic α1 receptors, which significantly reduces peripheral resistance. At the same time, it also has a moderate vasoconstrictor effect of blocking catecholamines. The central effect is to reduce blood pressure by stimulating serotonin-1A receptors and reducing the sympathetic feedback regulation of the medullary cardiovascular center. At the same time, it can also improve various hemodynamic indicators by reducing the side effect of reflex heart rate acceleration.

Ingredients

The main ingredient of this product is urapidil, whose chemical name is 6-{3-[4-(0-methoxy)-1-piperazinyl]-propyl}-1,3-dimethyluracil

Name Description Content CAS NO. Manufacturer
6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyluracilIngredients

Urapidil is a highly selective α1 receptor blocker with both peripheral and central effects. The peripheral vasodilator effect is mainly to block postsynaptic α1 receptors, which significantly reduces peripheral resistance. At the same time, it also has a moderate vasoconstrictor effect of blocking catecholamines. The central effect is to reduce blood pressure by stimulating serotonin-1A receptors and reducing the sympathetic feedback regulation of the medullary cardiovascular center. At the same time, it has no side effect of reflex heart rate acceleration and can also improve various hemodynamic indicators.

More
34661-75-1 9

Appearance

This product is white or off-white tablets.

Indication

This product is mainly used for essential hypertension, renal hypertension, and hypertension caused by pheochromocytoma.

Usage and Dosage

Adults usually start taking urapidil at 30 mg/day. If the effect is not obvious, the dose can be gradually increased to 60 mg or 120 mg per day over 1 to 2 weeks, taken orally in two divided doses. The dose can be increased or decreased appropriately based on age, symptoms, etc.

Adverse Reactions

Symptoms may include headache, dizziness, nausea, vomiting, fatigue, palpitations, arrhythmia, itching and insomnia. If the drug is overdose or the dose is increased too quickly in the initial stage of medication, it may cause dizziness, orthostatic hypotension, collapse and fatigue. Symptomatic treatment should be given if necessary.

Precautions

1. People who are allergic to this product. 2. Pregnant and lactating women.

Special Population Medication

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Pregnant and lactating women are prohibited from using this product. Precautions for the elderly: Not yet clear.

Drug Interactions

Not yet clear.

Storage

Keep in a sealed container. The validity period is tentatively set at two years.

Packaging Specification

30mg

Validity Period

24 months

Manufacturer

Heilongjiang Fuhe Pharmaceutical Group Co., Ltd.

  • Founded in:

    1994-12-28
  • Address:

    No. 1166, Zhengyang Street, Zhaodong City, Suihua City, Heilongjiang Province
  • Tax NO.:

    912312001313217015
  • Registered Funds:

    78.54 million yuan
  • Website:

  • Email:

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.